Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.2%) at 14,556 as of Monday, April 1, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 762 issues advancing vs. 2,184 declining with 121 unchanged. The Health Services industry currently sits down 1.0% versus the S&P 500, which is down 0.6%. On the negative front, top decliners within the industry include Align Technology ( ALGN), down 3.7%, Brookdale Senior Living ( BKD), down 2.4%, Agilent Technologies ( A), down 1.8%, Cooper Companies ( COO), down 1.7% and Mettler-Toledo International ( MTD), down 1.2%. TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today: 5. Thermo Fisher Scientific ( TMO) is one of the companies pushing the Health Services industry lower today. As of noon trading, Thermo Fisher Scientific is down $0.98 (-1.3%) to $75.52 on light volume Thus far, 688,752 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $75.39-$76.35 after having opened the day at $76.32 as compared to the previous trading day's close of $76.49. Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $27.4 billion and is part of the health care sector. The company has a P/E ratio of 22.3, above the S&P 500 P/E ratio of 17.7. Shares are up 19.9% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Thermo Fisher Scientific Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.